Tacrolimus ointment in the management of atopic dermatitis

Antonello Baldo
Mariana Cafiero
Paola Di Caterino
Luisa Di Costanzo
Department of Dermatology, University of Naples Federico II, Naples, Italy

Correspondence: Antonello Baldo
Dipartimento di Patologia Sistematica – Sezione di Dermatologia clinica, allergologica e venereologica – Università di Napoli Federico II – via S Pansini, 5 CAP 80131 Napoli, Italy
Tel +39 81 7462365
Fax +39 81 7462442
Email baldo@unina.it

Abstract: Atopic dermatitis (AD) is a chronic, relapsing, highly pruritic inflammatory skin disease. AD long-term treatment is usually required to control and prevent flares, and patients need a treatment that is safe and efficacious when applied continuously or intermittently over a prolonged period of time. The treatment options should be chosen according to age, clinical features and severity of the disease in every single patient. For the treatment of a chronic disease like AD, sustained tolerability and efficacy of the applied medications are essential. A topical immunomodulator, tacrolimus ointment, provides an alternative to topical corticosteroids without the associated adverse events. Tacrolimus is a macrolide lactone with unique immunomodulatory properties and strong anti-inflammatory activities and can be used without increasing the risk of infection or other non-application site adverse events, and without loss of effectiveness, in patients with AD.

Keywords: atopic dermatitis, tacrolimus, safety

Atopic dermatitis: general aspects

Atopic dermatitis (AD) is a chronic, relapsing, highly pruritic inflammatory skin disease that is particularly prevalent in the pediatric population, as 60% of the cases are diagnosed under the age of 1 year.1

It is the most common chronic disease of childhood and its incidence has been increasing during the recent decades in Western countries. The prevalence of AD is 10% to 20% in children and 1% to 3% in adults in temperate developed countries.2 AD has a chronic or chronically relapsing course with remissions and exacerbations of variable length. Typical clinical features include multiple lesions with erythema, excoriation, erosions accompanied by a serous exudate, accentuated skin markings (lichenification), fibrotic papules, severely dry skin, and a susceptibility to cutaneous infections.3 The main symptom is intense itching and excessive scratching can cause further damage such as excoriation, erosions and infections.4 The lesions have a typical age-dependent distribution pattern. In infants, nummular or seborrhoeic type eczema occurs on the cheeks, chin and trunk. In 1- to 4-year-old children, affected areas include extensor and sometimes flexural sides of the extremities, the hands, face, neck and perioral area. In 4- to 16-year-old children, flexural eczema predominates, with face, hands, feet and gluteal area affected. In adults, eczema most often occurs on the face, neck, upper body and extremities.5 AD is a clinical diagnosis. Hanifin and Rajka were the first to develop a diagnosis of this disease based on defined criteria,6 as described in Table 1. The histopathology is quite typical for any type of eczema with a superficial perivascular inflammatory infiltrate consisting mainly of T lymphocytes.7 The etiology of AD is unknown, but it is thought that a genetic predisposition exists with symptoms being triggered by various external and psychological factors.8

The genetic predisposition is strong. Its parental inheritance is complex and includes multiple gene interactions and environmental influences. AD, asthma
and elevated serum IgE have been linked to almost every chromosome, but no single gene can be implicated as the gene for the development of the skin disease.10

This hyper-IgE condition leads to a group of atopy-related diseases in many AD patients, such as asthma and allergic rhinitis, bronchial hyper-responsiveness and eosinophilic airway inflammation, atopic blepharoconjunctivitis.5–9

Pathophysiology of AD is characterized by dysregulated immune responses that consist of an increased systemic Th2 response and a combination of Th2 and Th1 responses in the skin lesions.11 Recent studies highlight the role of antigen-specific effector T-lymphocytes and down-regulatory CD4+ T-cells (Treg). These cells are responsible for the cutaneous inflammatory response through the production of inflammatory cytokines and the destruction of keratinocytes by apoptosis.12

Moreover in AD patients skin barrier function is deeply altered. Peptides with a molecular mass over 500 Da do not penetrate healthy normal skin, whereas in AD, environmental allergens of up to 20 kDa may penetrate the skin. This makes the skin susceptible to environmental factors such as detergents, irritants, allergens, microbial toxins, and physical or psychological stress.13 Defects of epidermal differentiation such as altered filaggrin expression weaken the epidermal barrier and predispose patients with AD to epicutaneous allergic sensitization as well as to physical, microbial and irritant skin damage. This barrier damage activates keratinocytes to produce inflammatory cytokines and starts the inflammatory cycle leading to T-cell activation, IgE-production and clinical AD.14

About 70% to 80% of patients with AD are considered to have classical, ie, IgE-associated or allergic, AD because they show elevated serum-IgE levels or positive skin prick test results for aeroallergens or food allergens, whereas the remaining 20% to 30% never show this kind of IgE-mediated sensitization and are considered to have non-IgE-associated or non-allergic AD.15

IgE-mediated sensitization may not yet be evident in infants or young children but it develops with increasing age. As the skin barrier function in AD is weakened, and the skin is deficient in antimicrobial peptides such as defensins and cathelins, various microbes are able to colonize the skin and cause secondary infections. The clinically relevant microbes in AD are Staphylococcus aureus, herpes simplex virus (HSV), and Malassezia (formerly known as Pityrosporum) yeast species.13

AD can significantly affect the child’s quality of life as patients are often distressed by their appearance, have low self-esteem and sometimes cannot enjoy normal routine activities and social interactions.5

### Treatment options in AD

AD tends to be a chronic disease with a relapsing course so that long-term treatment is usually required to control and prevent flares. Patients need a treatment that is safe and efficacious when applied continuously or intermittently over a prolonged period of time. The treatment options should be chosen according to age, clinical features and severity of the disease in every single patient.

Topical glucocorticosteroids (corticosteroids) have been the mainstay of AD treatment for the past few decades. They relieve the symptoms and inflammation of AD quickly but are officially indicated only for short-term use, usually for only 1 to 3 weeks. In long-term use of the compounds cutaneous side-effects are common, and include skin atrophy, bruising, telangiectasies, striae, steroid acne, hypertrichosis, tachyphylaxis, increased treatment tolerance (steroid resistance), and worsening of underlying secondary infections. Topical corticosteroids for treatment of eyelid and facial eczema may increase intraocular pressure and induce glaucoma and cataracts.16

Antihistamines are widely used for patients with AD, especially if allergic rhinoconjunctivitis and allergic asthma are co-existent. First-generation compounds such as hydroxyzine are useful for nocturnal pruritus due to their sedative effect. They do not seem to work on pruritus itself because,
Clinical, Cosmetic and Investigational Dermatology 2009:2

Effects include skin erythema, which is less with UVB (311–313 nm), UVA (320–400 nm) and PUVA (UVA usually with topical photosensitizing psoralens). Adverse long-term effects of azathioprine in AD are unknown.20

 Cyclosporine (cyclosporine A) is a non-myelosuppressive immunosuppressant, extensively studied in AD, and has shown good efficacy in adults and children. It acts by downregulating and inhibiting the cytokine production of Th2 cells. Treatment of AD with cyclosporine requires a regular follow-up by a dermatologist owing to its possible adverse effects: arterial hypertension, electrolyte imbalance, impaired glucose metabolism, Cushing’s syndrome, and osteoporosis, especially in long-term treatment.16–18

 Methotrexate is another old drug compound used similarly to azathioprine. Its main adverse effects include liver toxicity, anemia, thrombopenia, gastrointestinal dysfunction and pneumonitis.20 Other newer treatment modalities tried for severe treatment-resistant AD include mycophenolate mofetil, interferon gamma (IFN-γ), intravenous immunoglobulin (IVIG) and the new TNF-α inhibitors or “biologic” treatments designed for rheumatoid arthritis and psoriasis20 (Table 2).

 However, all these therapeutical options will diminish but not eliminate the need for topical treatments, so that they are considered as secondary treatments of AD, combined with topical corticosteroids when these are not sufficient to control the disease. They may diminish the need for topical corticosteroids but do not replace them.21

 Several types of ultraviolet (UV) light therapy can be associated with topical treatment: UVB, narrow-band UVB (311–313 nm), UVA (320–400 nm) and PUVA (UVA usually with topical photosensitizing psoralens). Adverse effects include skin erythema, which is less with UVB treatment, skin burning and risk for skin malignancies with cumulative UV dose.22

 For the treatment of a chronic disease like AD, sustained tolerability and efficacy of the applied medications are essential. A topical immunomodulator, tacrolimus ointment, provides an alternative to topical corticosteroids without the associated adverse events.

**Mechanism of action of tacrolimus**

Tacrolimus ointment is a topical calcineurin inhibitor (TCI) and was the first of this class of topical preparations to be developed particularly for the treatment of AD.23

 Tacrolimus is a macrolide lactone with unique immunomodulatory properties and was originally isolated in Japan in 1980 from the fungus-like bacterium Streptomyces tsukubaensis. It was first approved for the treatment of AD in Japan in 1999, with approvals following for the USA in 2000 and for The European Union in 2002.24–26

 Tacrolimus is absorbed passively into skin, particularly in affected skin, and reduces skin inflammation and pruritus in AD, blocking T-cells activation by binding to the cytosolic immunophilin receptor (macrophilin-12) to form a complex that inhibits the activity of the enzyme calcineurin. Calcineurin normally dephosphorylates a cytosolic transcription factor, the nuclear factor of activated T-cell protein (NF-ATp), allowing it to travel to the nucleus, where it initiates the activation of a variety of genes involved in T-cell activation.25,27

 Because this transcription factor is essential for the production of IL-2 and other cytokines (INF-gamma, IL-3, IL-4, IL-5), prevention of its translocation effectively inhibits Th1-cell and Th2-cell activation. Calcineurin inhibition can also decrease production of both the proinflammatory cytokines, tumor necrosis factor and granulocyte-macrophage colony-stimulating factor, necessary for the maturation of dendritic cells.28–31

 Tacrolimus effects on the immune system (including antigen-presenting cells [APC] T-lymphocytes, mast cells and keratinocytes) are well studied. In AD pathogenesis, APC are involved: CD1a+ epidermal APC are more represented in untreated lesions of the disease, but it has been demonstrated that treatment with topical tacrolimus reduces CD1a+ expression.25,32,33 Several in vivo animal studies confirm that tacrolimus can inhibit the effective phase of contact hypersensitivity (in mice) and partially the sensitization phase of contact hypersensitivity.

 Moreover further studies have demonstrated that in vivo keratinocyte apoptosis induced by activated T-cells is significantly reduced after successful topical treatment with tacrolimus. This effect is mediated by 2 major mechanisms
directed on T-cells or keratinocytes: direct T-cell inhibition and Fas-mediated keratinocyte apoptosis inhibition of eczematous lesions.  

Therefore topical tacrolimus has strong anti-inflammatory activities and a pronounced immunosuppressant potential.  

**Tacrolimus ointment – clinical studies**

**Efficacy – short-term studies**

Efficacy of tacrolimus has been demonstrated in many short-term studies.

In several vehicle-controlled short-term studies, tacrolimus ointment, both 0.03% and 0.1%, was significantly more effective than the vehicle in treating adults and children affected by AD, with no significant differences between the two different concentrations.  

Tacrolimus 0.03% and 0.1% ointments have been compared with topical steroids. In a randomized, double-blind study in 2- to 15-year-old children affected by moderate to severe AD, both concentrations showed a significantly greater improvement than 1% hydrocortisone acetate. In adult patients with moderate to severe AD, tacrolimus 0.1% was as effective as hydrocortisone-17-butyrate, and both were superior to the 0.03% ointment.  

In a 3-week study in a pediatric population, tacrolimus 0.03% ointment applied once or twice daily had greater efficacy than hydrocortisone 1% acetate applied twice daily, even though, especially in patients with more severe baseline disease, double daily application of tacrolimus was more effective than single application.  

Even compared with cyclosporine, tacrolimus has been demonstrated to be superior: a 6-week study showed that efficacy of 0.1% ointment was better than that of oral cyclosporine 3 mg/kg.  

**Efficacy – long-term studies**

Efficacy of tacrolimus ointment has been assessed in several thousand adult and pediatric patients in long-term, open-label, non-comparative, multicenter studies lasting for 12 to 48 months, in Europe and the US. In both adult and pediatric populations with moderate to severe AD, 0.1% tacrolimus ointment has showed rapid and protracted improvement.

---

**Table 2 Principal systemic treatment for atopic dermatitis**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Mechanism of action on AD</th>
<th>Adverse effects</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Corticosteroids</strong></td>
<td>Reduction of number and activity of lymphocytes</td>
<td>Systemic effects: hypothalamic–pituitary–adrenal axis suppression, reduced linear growth in children, and bone density changes in adults</td>
</tr>
<tr>
<td></td>
<td>Reduction of inflammatory cytokines (IL-12 and INF-γ)</td>
<td>Local effects: skin atrophy, bruising, telangiectasies, striae, steroid acne, hypertrichosis, tachyphylaxis, steroid resistance, worsening of underlying secondary infections</td>
</tr>
<tr>
<td></td>
<td>Reduction of cyclooxygenase, platelet activating factor</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Vasoconstriction and reduction of small vessels permeability</td>
<td></td>
</tr>
<tr>
<td><strong>UVB-treatment</strong></td>
<td>Suppression of Th2 chemokine production suggests that UVB exposure to the skin suppresses infiltration of Th2 cells to the epidermis</td>
<td>Skin erythema, skin burning, risk for skin malignancies</td>
</tr>
<tr>
<td><strong>Cyclosporine</strong></td>
<td>Inhibition of IL-2 production by blocking the function of the enzyme calcineurin (CaN)</td>
<td>Arterial hypertension, nephrotoxicity, and immunosuppression</td>
</tr>
<tr>
<td><strong>Methotrexate</strong></td>
<td>Inhibition of synthesis of purines and pyrimidines required for cellular proliferation of lymphocytes</td>
<td>Anemia, thrombopenia, gastrointestinal dysfunction, and pneumonitis</td>
</tr>
<tr>
<td><strong>Antihistamines</strong></td>
<td>Inhibition of peripheral histamines receptors with reduction of vasodilatation and itching, inhibition of central histamine receptors with sedative effect, local anesthetic effect</td>
<td>Excessive sedation</td>
</tr>
<tr>
<td><strong>Azathioprine</strong></td>
<td>Inhibition of purine synthesis with consequent stop in synthesis of DNA, RNA, and proteins; it may also interfere with cellular metabolism and inhibit mitosis: the proliferation of cells, especially leukocytes</td>
<td>Bone marrow suppression and oncogenic potential, gastrointestinal symptoms. Leukopenia or infection fever or chills, cough or hoarseness, lower back or side pain, painful or difficult urination, tiredness or weakness</td>
</tr>
<tr>
<td><strong>Mycophenolate mofetil</strong></td>
<td>Inhibition of inosine monophosphate dehydrogenase (IMPDH), with following de novo synthesis pathway of guanosine nucleotides (on which T and B lymphocytes are critically dependent for their proliferation)</td>
<td>Bone marrow suppression, peripheral edema, arrhythmia, artralgia</td>
</tr>
<tr>
<td><strong>TNF-α inhibitors</strong></td>
<td>Through inhibition of TNF-α, which has a great inflammatory activity, reduction in epidermal hyperplasia neoangiogenesis and itching</td>
<td>Increased risk of infection, especially reactivation of tuberculosis; increased risk of lymphoproliferative diseases, worsening of heart failure; local reactions</td>
</tr>
</tbody>
</table>
in efficacy parameters. Children treated with 0.03% ointment intermittently for 12 to 29 months and with 0.1% ointment periodically if the 0.03% was insufficient, showed substantial improvement in efficacy parameters, including pruritus within 2 weeks, and maintained the result throughout the study.

A multicenter, randomized, double-blind, controlled study of 6 months compared tacrolimus ointment 0.1% on the trunk and extremities with hydrocortisone-17-butyr and on the face and neck with 1% hydrocortisone acetate in an adult population with moderate to severe AD. Tacrolimus achieved greater improvement in all efficacy parameters, and a higher percentage of the patients showed at least a 60% response (72.6% vs 52.3%, \( p < 0.001 \)).

**Tacrolimus and safety**

Safety of tacrolimus ointment has been demonstrated in short- and especially long-term studies, as it has been demonstrated that systemic absorption of tacrolimus from topical application is largely minimal. Topical treatment can lead to blood concentrations of a maximum of approximately 3% of those of transplant patients using systemic tacrolimus, with no signs of accumulation of tacrolimus after repeated application.

The most common adverse events of application of tacrolimus ointment (~60% of patients) are limited to the site of application, such as pruritus and “skin burning”, with burning sensation, pain, stinging, erythema, soreness and flushes especially after alcohol ingestion. Most episodes of skin burning last less than 10 minutes and most episodes of pruritus last less than 1 hour. The prevalence of application site adverse events, in particular skin burning and pruritus, more frequent in adults than in children, is highest during the first few days of treatment and then declines. For most patients who experienced an application site adverse event, the severity of the worst episode is mild or moderate.

No case of skin atrophy has been reported and, moreover, long-term treatment with tacrolimus ointment has been associated with improvements in collagen synthesis and skin thickness.

Sun avoidance is recommended during tacrolimus therapy, which led to black box warnings in the US on increased cancer risk from topical tacrolimus, despite the fact that, to date, the development of skin cancer as result of tacrolimus ointment treatment has not been reported.

However, a recent large case-control study with a cohort of almost 290,000 patients receiving different AD treatments showed that the main factor associated with increased lymphoma risk is AD severity, whereas there was no increased risk of lymphoma in patients treated with topical calcineurin inhibitors.

One of the most discussed adverse effects of topical tacrolimus was the increase of infections but most of these are considered mild or moderate in severity and were not confirmed by the study investigators to be related to the use of tacrolimus ointment. Nevertheless there is no evidence of an increase in the risk of cutaneous infections with long-term use of tacrolimus ointment, and the incidence of cutaneous infections in the long-term studies is comparable with that observed with 12-week application.

No clinically meaningful changes in mean or median values for hematology, indicators of hepatic or renal function, serum electrolytes, blood glucose and serum IgE have been observed.

According to a recent systemic review on topical treatment of AD, significant local or systemic adverse events are mainly associated with use of topical corticosteroids. These findings suggest that tacrolimus ointment may be a better choice for long-term treatment to control and prevent AD flares in all patients, including children.

**Topical tacrolimus in practice**

AD is a disease resulting from the interaction of genetic, environmental and immunological factors and presents many clinical aspects. Therefore, patients suffering from AD require individual management.

Many studies have demonstrated that tacrolimus ointment is effective for the treatment of AD. Tacrolimus ointment is suitable for the short and intermittent long-term treatment of moderate to severe AD in patients over 24 months old who are not adequately responsive or are intolerant to conventional therapies, such as topical corticosteroids.

A significant improvement of the disease is notable within 1 week of starting tacrolimus therapy. For adult and pediatric patients, the ointment should be applied at the first sign of dry skin or pruritus. In adult patients the treatment should be initiated with tacrolimus 0.1% twice daily for 3 or 4 weeks; later on the concentration and the dosage can be reduced.

In pediatric patients, it is advised to begin the treatment with tacrolimus 0.03% twice daily for 3 or 4 weeks, followed by once-daily application until the lesions improve.

Potent topical corticosteroids are used reactively to treat AD flares. Unlike potent corticosteroids, tacrolimus ointment can be used to reduce the incidence of disease flares and also the severity of flares without the risk of corticosteroid-related adverse events.
Furthermore, in contrast to topical corticosteroids, tachyphylaxis or rebound are not observed, even in long-term tacrolimus treatment. Moreover, tacrolimus ointment application makes the therapy of AD easy.

It is effective as monotherapy and its safety profile enables its use on all affected areas of the body (including face, neck and fold sites) for as long as necessary, without the need for concomitant corticosteroid therapy. This is one of the most important differences between tacrolimus and topical corticosteroid regimens routinely used. In fact, topical steroids therapy includes a less potent preparation on sensitive skin areas and a more potent preparation on other affected areas for a short time to diminish adverse-related effects.

Although tacrolimus has potent immunosuppressive ability, it does not seem to increase Staphylococcus aureus colonization, probably because of its healing effects on the skin, which can reduce the ability of adhesion molecules necessary for staphylococcal colonization.

No studies have reported significant enhancement of viral or bacterial infections in patients treated with tacrolimus ointment.

It is important to advise patients using tacrolimus ointment to avoid a solarium, to minimize exposure to sunlight, and to use sunscreen, even though it is not a photo-sensitizer. Moreover the risk of photo-carcinogenicity with topical tacrolimus is small in clinical practice.

In conclusion, 0.03% and 0.1% tacrolimus ointment can be used daily for periods of up to 1 year for AD treatment in patients, including pediatric patients, without increasing the risk of infection or other non-application site adverse events, and without loss of effectiveness.

Disclosures
The authors declare no conflicts of interest or sources of funding.

References


62. Reitamo S. European Tacrolimus Ointment Study Group. 0.1% Tacrolimus ointment is significantly more efficacious than a steroid regimen in adults with moderate to severe atopic dermatitis. 12th Congress of the European Accademy of Dermatology and Venereology, St Julian’s, Malta. 27 February – 1 march. Poster presentation. p. 1–28.


